NNZ-2591 positive effects in Phelan-McDermid syndrome model
(WorldNews Health)

Neuren (NEU) - ASX Announcement 18 February 2019 NNZ-2591 demonstrates positive effects in Phelan-McDermid syndrome pre-clinical model Melbourne, Australia, 18 February 2019: Neuren Pharmaceuticals (ASX: NEU) today announced that its drug candidate NNZ-2591 has demonstrated positive effects in a pre-clinical model of Phelan-McDermid syndrome (PMS). PMS is a rare genetic condition in which the most common characteristics are intellectual disability, delayed or absent speech, symptoms of autism, low muscle tone, motor delays, and epilepsy. There is currently no treatment specifically for PMS. Neuren anticipates that PMS meets the criteria for Orphan Drug designation. NNZ-2591 was tested in the...